Company: Macrophage Pharma
Job title: Director of Business Development
Elisabeth has 20 years’ experience of R&D and commercialisation of translational research through licensing and spin-outs.
Prior to joining Macrophage Pharma, Elisabeth worked for Cancer Research Technology Ltd (CRT), the development and commercialisation arm of Cancer Research UK, and served as a non-executive Director of Arquer Ltd and Azeria Therapeutics Ltd. Prior to joining CRT, Elisabeth was Head of Research at KS Biomedix, a UK quoted Biopharmaceutical company. Elisabeth holds a PhD from the Medical Faculty, Lund University, Sweden.
Regulating Macrophage Polarization to Create a Tumor Suppressive Environment 2:30 pm
• Discuss macrophage phenotypes, the tumour microenvironment and implications for immune response and prognosis • Review Esterase Sensitive MotifTM drugs to control polarity and lock specific phenotypes • Explore potential targets and immuno-oncology combinationsRead more
day: Day One